ArticleInflammation2026
Deucravacitinib Inhibits Synovial Fibroblast Activation Via TYK2/STAT3 and PI3K/Akt Signaling Pathway.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis, primarily affecting symmetric small joints. Deucravacitinib, a novel oral highly selective tyrosine kinase 2 (TYK2) inhibitor, has shown promise in treating various immune-mediated diseases. This study aimed to explore the therapeutic effects and underlying mechanisms of deucravacitinib in RA.
methodsThe anti-proliferative effects of deucravacitinib were assessed using the CCK-8 assay, while its pro-apoptotic activity in MH7A cells was evaluated via flow cytometry. Cell wound healing assay and transwell assays were employed to determine the migration and invasive capabilities of MH7A cells. RNA sequencing (RNA-seq) was conducted to identify differentially expressed genes following deucravacitinib treatment. Network pharmacology and molecular docking analyses were utilized to predict potential anti-arthritic targets. The impact of deucravacitinib on the TYK2/STAT3 (signal transducer and activator of transcription) and PI3K(phosphoinositide3-kinase)/AKT(protein kinases B) signaling pathways was investigated. In vivo, a collagen-induced arthritis (CIA) mouse model was treated with low-dose deucravacitinib (5 mg/kg/d) for 21 days, and its anti-arthritic effects were evaluated.
resultsIn vitro, deucravacitinib significantly inhibited MH7A cell proliferation and induced apoptosis, while also reducing cell migration and invasion. Mechanistically, deucravacitinib upregulated Bax (Bcl-2-associated X protein) expression and downregulated Bcl-2 (B-cell lymphoma 2), MMP-2(Matrix Metalloproteinase-2), and MMP-9(Matrix Metalloproteinase-9) mRNA levels, likely through inhibition of the TYK2/STAT3 and PI3K/AKT pathways. In vivo, deucravacitinib alleviated toe swelling, reduced arthritis scores, and decreased mRNA levels of Bcl-2, MMP-2, and MMP-9 in CIA mice. Histopathological analysis revealed improved joint integrity and reduced bone erosion.
conclusionDeucravacitinib demonstrates significant anti-arthritic potential by inhibiting synovial fibroblast proliferation, migration, and invasion while promoting apoptosis. These effects are mediated through suppression of the TYK2/STAT3 and PI3K/AKT signaling pathways, suggesting its promise as a therapeutic agent for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.